8/7/2007

Medical experts cite a desperate need for research on the muscle-wasting disease myasthenia gravis, but the small patient population discourages such efforts. "It's just not cost-effective" for drug companies to work on a drug for such a small pool of patients, said one doctor.

Full Story:
Forbes

Related Summaries